



NEW! Late-Breaking Research Submission Guidelines

Submission Opens on November 15, 2024, and Closes on January 31, 2025

The SCA will be accepting late-breaking research manuscripts for the 2025 Annual Meeting in Montreal until January 31, 2025. Late-breaking research manuscripts should address a timely, important research question and represent science that is anticipated to either change clinical practice or to significantly advance the field of cardiovascular research.

IMPORTANT INFORMATION

- Submission system **opens on November 15, 2024**.
- Submission system **closes at 11:59 PM (Eastern Time) on January 31, 2025**.
 - Additional submissions will not be accepted after the submission system closes.
 - If you do not receive an email confirmation of your submission within 30 minutes of finalizing your submission, please contact SCA Program Team at kflowers@scahq.org.
 - Co-authors must complete their bio and disclosure forms by January 31, 2025.
 - The submission will not be reviewed unless **all** listed authors complete a disclosure form by the deadline.
 - Notifications regarding selection will be sent by February 21, 2025.

GENERAL REQUIREMENTS FOR SUBMISSION

- Manuscripts must be in English.
- Manuscripts for consideration must have a publication date after May 1, 2024 or are currently under review / in revision at a journal, or in pre-print / in press. Manuscripts on a preprint server that are not yet peer reviewed will also be eligible for consideration.
- The presenting author of the research project must have completed registration for the 2025 SCA meeting and be available in person at the meeting to present their work.
- Each registrant can only submit one manuscript for consideration.
- Each principal investigator can only submit one of their eligible manuscripts for consideration.
- Abstracts are not sufficient for submission.

Evaluation and Outcomes:

- Late breaking research manuscripts submitted will be screened by a subset of the Scientific Program Committee in consultation with the Research Committee for relevance to the SCA's mission.
- The two most relevant articles will be presented as a podium presentation during the COR-PM/ Research track program.

INSTRUCTIONS FOR ONLINE SUBMISSION

Submission Content and Format Rules

- All submissions will include four (4) sections. The content of those sections will depend on the type of submission:
 - Background / Introduction

- Methods / Case Report
- Results / Discussion
- Conclusion
- Submissions must be in English.
- Submissions must be single-spaced.
- Submissions are limited to a 3,300-character count, which includes body text and spaces. Tables and graphs do not count against the character count.
- Do **not** include the following in the submission body:
 - Names of authors or institutions
 - References, credits, or grant support
- Titles should be short and specific and should **not** contain abbreviations, quotation marks, or all capital letters.
- Use generic drug/product names rather than trade names.
- Standard abbreviations may be used but should be kept to a minimum.
- Tables, figures, images, or other graphics will only be accepted as still images in the following file formats: .jpg, .png, .tiff, or .bmp.
- Submissions should include the best available evidence and should not include content that is biased or promotional in nature.

General Rules

- Only manuscripts submitted using the online submission system will be considered.
- The submitting author will be designated as the presenting author and must attend the 2025 Annual Meeting in Montreal, Quebec, Canada if the submission is accepted.
- All communication from/to the SCA will be with the submitting/presenting author only.
- Submissions are not to be completed by other parties on the author's behalf.
- The submitting/presenting author must complete a disclosure of relevant financial relationships at the time of submission.
- Co-authors will receive emailed requests for relevant financial disclosures after the submission has been submitted. If a co-author fails to submit his/her disclosure form, the submission will be disqualified.
 - If there is an extenuating circumstance where an author will be unavailable to submit conflict of interest information, please contact SCA at kflowers@scahq.org.
- Once the manuscript is submitted, no revisions are permitted.
- Manuscripts must summarize an original contribution.
 - If there is any question regarding similarity to earlier work or possible duplication, it is the responsibility of the submitting author to contact SCA at the time of submission (kflowers@scahq.org).
- Submitting/presenting author will attest that all co-authors of the submission have granted consent for the material to be submitted for presentation, and that the submitting/presenting author has been granted the right by all co-authors to act on their behalf.
- Submitted text and images must be HIPPA compliant, including masking of all patient identification material. Images with patient identifiers will not be considered for presentation.
- Submitting/presenting author must attest that the research was approved by his/her institution's International Review Board (IRB) and that informed consent/assent was obtained from each subject and/or parent or guardian.
- Institutional quality improvement committee approval is not sufficient without also having IRB approval or a written statement from the IRB that the study is IRB exempt.
- SCA reserves the right to withdraw a submission at any time.
- In the event that a change in presenting author must be made after the submission, the SCA must be notified in writing as soon as possible, email can be sent to kflowers@scahq.org.

- Authors will not be provided complimentary registration or any other financial support. Presenting authors are expected to register for and attend the meeting.
- **If a different presenting author must be designated after submission, please adhere to the following:**
 - The presenting author must be a co-author listed on the manuscript at the time of submission. Please notify the SCA at kflowers@scahq.org to make this change.
 - Presenter changes made after **February 28, 2025** will not be reflected in any printed or online materials or applications.
 - If a co-author cannot be identified to present the research, the submission must be withdrawn from presentation. Please notify the SCA immediately at kflowers@scahq.org.

SUBMISSION REVIEWS

All submissions undergo a blinded peer-review process and will be reviewed on content organization and clarity, relevance to SCA membership, and methodological strength of study design. Submissions should be well written in a style that is understandable to a non-specialist. The “message” is easily understood by the reader without having to re-read the submission several times.

- **Background:** Clearly stated study background. If a case report or case series, the reason for presenting the case(s) is clearly stated instead of a study hypothesis.
- **Methods:** Clearly describes the method of data collection ((e.g.) prospective data collection or chart review). Statistical methodologies are clearly described.
- **Results:** Data/findings are presented in a manner (description +/- graphics) that is easy for the reader to understand. For case presentations, the appropriate clinical details are included. Descriptive and statistical results are stated. Tables, figures, images, or other graphics add to what is described in the submission.
- **Conclusion:** Well-stated so that it is obvious how the data supports or refutes the stated conclusions. Case report conclusions should clearly state how observations support a clinical or scientific principle or hypothesis worthy of future study.